GLP-1s & Weight Loss

Semaglutide

Evidence

What is semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk. It is a modified peptide analogue of human GLP-1, engineered to resist rapid enzymatic degradation and to bind albumin strongly enough to give an approximately one-week half-life.

Its primary receptor is GLP-1R. It does not directly agonize GIPR, the glucagon receptor or amylin receptors, which makes it fundamentally different from dual or triple agonists such as tirzepatide or retatrutide.

There is no single semaglutide dose

The appropriate dose depends on product, route, formulation, indication, age, tolerability and treatment goal. 0.25 mg once weekly is an injectable initiation dose, not a universal therapeutic or maintenance dose.

FDA-approved semaglutide products

• Wegovy injection: chronic weight reduction, long-term weight maintenance, cardiovascular-risk reduction in adults with established cardiovascular disease and overweight or obesity, and noncirrhotic MASH with F2-F3 fibrosis. Injectable dosing now extends to 7.2 mg once weekly for selected adults who need additional weight reduction.
• Wegovy tablets: adult weight reduction, long-term weight maintenance and cardiovascular-risk reduction. Escalation is 1.5 mg daily, then 4 mg, then 9 mg, then 25 mg, with 25 mg once daily as maintenance.
• Ozempic injection: type 2 diabetes, cardiovascular-risk reduction in appropriate adults with type 2 diabetes, and kidney and cardiovascular-risk reduction in adults with type 2 diabetes and chronic kidney disease.
• Ozempic tablets: newer oral formulation using 1.5 mg daily, then 4 mg, then 9 mg.
• Rybelsus: older oral formulation using 3 mg, then 7 mg, then 14 mg daily.

Formulation warning: Rybelsus, Ozempic tablets, Wegovy tablets and injectable semaglutide are not milligram-for-milligram equivalents.

Evidence strength

Overall: very strong evidence, but the evidence belongs to specific products, formulations, routes and indications.

Weight-loss evidence

STEP 1. Adults with obesity, or overweight plus a weight-related condition, without diabetes. At 68 weeks, semaglutide 2.4 mg produced about 14.9% mean weight loss versus about 2.4% with placebo. Strong randomized human evidence.

STEP UP. The Phase 3b trial randomized 1,407 adults with obesity without diabetes to semaglutide 7.2 mg, 2.4 mg or placebo. At 72 weeks, mean body-weight change under the treatment-policy estimand was about:

• 7.2 mg: -18.7%
• 2.4 mg: -15.6%
• Placebo: -3.9%

The larger figure of about 20.7% for 7.2 mg comes from the efficacy (trial-product) estimand and is a different measure from the treatment-policy estimate.

7.2 mg adds exposure, not a new mechanism. At 7.2 mg semaglutide still acts at GLP-1R; no new receptor switches on at the higher dose. Higher systemic exposure produced greater average weight reduction, more GI adverse effects and substantially more dysesthesia: higher efficacy on average, with an added tolerability burden.

Long-term treatment. Semaglutide's approved and investigational obesity programs are chronic-treatment programs, not 8- or 12-week cycles. STEP 5 followed treatment through 104 weeks and found about 15.2% mean weight reduction with continued treatment. SELECT continued clinical follow-up over years.

What happens after stopping

The STEP 1 extension followed participants after treatment withdrawal. During the year after stopping, participants regained about 11.6 percentage points of body weight, roughly two-thirds of their prior semaglutide-associated weight loss, and many cardiometabolic improvements moved back toward baseline.

Weight regain after discontinuation is common. It does not show that semaglutide permanently damages metabolism, causes narcotic-like dependence, destroys endogenous GLP-1 function or makes future weight loss impossible. The biological drivers of obesity persist after treatment; when semaglutide is withdrawn, its appetite-regulating and metabolic effects diminish and substantial regain is common.

Cardiovascular evidence: SELECT

SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes, who received semaglutide 2.4 mg once weekly or placebo. Major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo (hazard ratio 0.80), about a 20% relative risk reduction.

This outcome evidence is real, and later analyses suggest the cardiovascular effect is not explained solely by the amount of weight lost. Semaglutide reduces major cardiovascular-event risk in the specific high-risk population studied and covered by the Wegovy indication.

Kidney evidence: FLOW

FLOW included 3,533 adults with type 2 diabetes and chronic kidney disease, treated with semaglutide 1 mg weekly or placebo. The major kidney and cardiovascular composite occurred significantly less often with semaglutide (hazard ratio 0.76), about a 24% relative risk reduction. Additional findings included slower eGFR decline, lower major cardiovascular-event risk, lower cardiovascular mortality and lower all-cause mortality.

Semaglutide has proven kidney-outcome benefits in people with type 2 diabetes and CKD, while severe vomiting, diarrhea or poor intake can still cause volume depletion and secondary acute kidney injury. Both statements are true.

MASH

Wegovy injection is FDA approved under accelerated approval for noncirrhotic MASH with F2-F3 fibrosis in adults. Labeling distinguishes this indication from weight reduction. Interim Phase 3 histologic data (ESSENCE) showed substantially more MASH resolution without worsening fibrosis, and more fibrosis improvement without worsening MASH, with semaglutide than with placebo.

Expected results timeline

At a glance

Protocol logic check

Bottom line

Semaglutide has exceptionally strong human evidence. The main problem today is evidence transfer. Approved Wegovy evidence does not automatically apply to a third-party lyophilized vial; Ozempic dosing is not Wegovy dosing; injectable doses cannot be converted directly into oral milligrams; and Rybelsus, Ozempic tablets and Wegovy tablets cannot be compared by the number printed on the tablet.

The 7.2 mg Wegovy dose is a legitimate FDA-approved higher-dose weight-management option. It is not a universal maintenance dose and not automatically the right dose for another indication, and 2026 labeling shows altered skin sensations occurring much more often at 7.2 mg than at 2.4 mg.

SELECT showed a 20% relative reduction in major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes, and FLOW showed a 24% reduction in its major kidney and cardiovascular composite in people with type 2 diabetes and CKD. Semaglutide is more than a cosmetic weight-loss peptide.

Weight regain after stopping is common, reflecting the chronic biology of obesity and the loss of ongoing drug effect, not permanent metabolic damage. FDA's 2026 review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists.

Once-weekly injection remains the best-supported injectable schedule. Split dosing is pharmacokinetically plausible but has not shown clinical superiority, and every-five-day dosing at the same nominal dose increases average exposure. For compounded or research-vial semaglutide, a syringe unit is not a dose, a clinical milligram amount in an unknown vial does not make the vial clinically equivalent, a high-purity COA does not prove the API is the approved molecular form, and added B12, B6, carnitine or NAD+ does not create a proven synergistic formulation.

Evidence hierarchy: FDA-approved product and indication, then randomized clinical trial evidence, then cardiovascular, kidney and liver outcome evidence, then formulation-specific pharmacology, then controlled experimental dosing, then compounded-product evidence, then community protocols, then anecdote.

Dosing evidence

Dose warning: semaglutide has no universal "typical dose". A 0.25 mg weekly injection is an initiation dose. Approved dosing ranges from product-specific injectable titration through traditional 2.4 mg maintenance and, for selected adult weight-management patients, 7.2 mg weekly. Oral products use entirely different, formulation-specific daily milligram scales.

Units warning: milligrams are the dose; syringe units are volume. The number of units to draw depends entirely on the concentration in the vial, so the same 10 units can be different semaglutide doses in different preparations. FDA has documented serious compounded-semaglutide dosing errors caused by confusion between mg, mL and syringe units, including cases in which patients gave themselves about 5 to 20 times the intended dose.

Wegovy injection: weight management

1.7, 2.4 and 7.2 mg are not three equivalent maintenance choices. The hierarchy is: initiation at 0.25 mg weekly; traditional maintenance at 1.7 or 2.4 mg; usual recommended maintenance at 2.4 mg; a higher-dose adult weight-management option of 7.2 mg in selected adults after appropriate escalation.

MASH dosing

MASH maintenance centers on 2.4 mg once weekly, with 1.7 mg where 2.4 mg is not tolerated. 7.2 mg being the highest approved weight-reduction dose does not make it the MASH dose: the same molecule uses different doses for different indications.

Ozempic injection: type 2 diabetes

The initiation dose is 0.25 mg weekly, followed by 0.5 mg weekly, with escalation to 1 mg and then 2 mg weekly when additional glycemic control is needed. Ozempic 2 mg is not Wegovy 2.4 mg, and neither is Wegovy HD 7.2 mg, even though all contain the same active molecule.

Oral semaglutide

FDA provides switching relationships between Rybelsus and Ozempic tablets rather than assuming numeric milligram equivalence.

Oral milligrams are not injectable milligrams. 25 mg oral daily versus 2.4 mg injected weekly does not mean the oral product is far stronger. Oral semaglutide has very limited gastrointestinal absorption and depends on specialized formulation technology. Dose numbers cannot be compared across routes without considering bioavailability and formulation.

Timing

Oral: timing matters. FDA instructions involve an empty stomach, morning administration, a small amount of plain water, and waiting before food, drinks or other oral medication. Oral fasting requirement: yes. Oral morning administration: yes.

Injectable: once weekly on the same day each week, at any time of day, with or without food. Morning required: no. Night required: no. Fasting required: no. Workout timing: no.

Half-life and "wearing off"

The human injectable half-life is about one week, which supports once-weekly dosing. People may feel more appetite, less nausea or less fullness toward the end of a dosing interval, but with a one-week half-life substantial semaglutide remains in the body at the next scheduled injection. Returning hunger does not mean the drug has been eliminated.

Community protocols

Community protocol pages commonly keep the approved-style sequence of 0.25, 0.5, 1, 1.7 and 2.4 mg, but frequently move it into research vials, custom bacteriostatic-water concentrations, syringe-unit calculations, split-dose schedules, accelerated titrations and short "cycles". A real clinical milligram dose does not make a different formulation, schedule or vial clinically validated. Splitting a weekly dose, injecting every three to five days, microdosing, changing titration speed or putting branded dose numbers into an unverified research vial creates a different protocol.

• Split dosing: some users divide a weekly amount into two injections about every 3.5 days to lower peak concentration, raise the trough and flatten the concentration curve. The pharmacologic logic is plausible, but no major randomized semaglutide obesity trial shows that twice-weekly injection gives greater weight loss, fewer GI effects, less dysesthesia, better cardiovascular outcomes, better adherence or better long-term safety. It is a mechanistically plausible but clinically unvalidated modification.
• Every-five-day dosing: giving the same nominal dose every five days instead of every seven increases the average dose over time. 1 mg every 7 days is about 1 mg/week; 1 mg every 5 days is about 1.4 mg/week, roughly 40% more average weekly exposure. Any change in efficacy or side effects after shortening the interval cannot be attributed to smoother dosing alone.
• PRN dosing: injecting whenever hunger returns does not match semaglutide pharmacology or the approved program. Because semaglutide has a long half-life, accumulates with repeated dosing and is titrated gradually, hunger-triggered dosing is not evidence based.
• Microdosing: some community protocols use very small weekly doses such as 0.05, 0.1, 0.15 or 0.2 mg for food noise, maintenance, inflammation, metabolic health or mild appetite control without substantial weight loss. Very-low-dose human exposure existed during early drug development, but a clinically validated semaglutide microdosing protocol does not exist.

Treatment duration

Semaglutide is not a cycle-and-reset peptide; clinical studies run from months to years. The clinical model is chronic treatment when clinically indicated. 8 weeks on / 4 weeks off, 12-week cycles, periodic washouts and weekend breaks are not established.

Receptor reset: there is no established requirement for a GLP-1 receptor reset, detox, washout or resensitization cycle. The four-week titration steps exist mainly for tolerability, not receptor recovery.

Mechanism

Semaglutide activates GLP-1R. Major clinical effects include glucose-dependent insulin secretion, reduced inappropriate glucagon release, increased satiety, reduced appetite, altered food reward, reduced caloric intake and changes in gastric emptying. The main weight-loss mechanism is reduced energy intake.

Is semaglutide a "fat burner"?

Not in the conventional pharmacologic sense. It does not act like clenbuterol, a sympathomimetic, a thermogenic drug or retatrutide's glucagon agonism. Semaglutide promotes weight loss mainly by altering appetite, satiety and energy intake.

Gastric emptying

Semaglutide can slow gastric emptying, particularly during initiation and escalation, and the size of the effect may change with chronic treatment. Severe GI motility problems can occur in some patients, but the pharmacologic effect on gastric emptying is not universal permanent gastroparesis.

Lean mass

Weight loss includes both fat mass and lean mass. Some lean-tissue loss is expected during substantial weight reduction; the amount depends on baseline body composition, the degree and speed of weight loss, nutrition and resistance training. Semaglutide does not selectively remove only fat, and it is not directly toxic to muscle.

Contraindications

Formal contraindications

• personal history of medullary thyroid carcinoma (MTC)
• family history of MTC
• multiple endocrine neoplasia type 2 (MEN2)
• serious hypersensitivity to semaglutide or formulation components

Thyroid C-cell tumor warning

Semaglutide carries a boxed warning based on rodent thyroid C-cell tumors. FDA states that whether semaglutide causes MTC in humans is unknown. Rodent C-cell tumors are not proof that semaglutide causes thyroid cancer in humans.

Routine serum calcitonin or thyroid ultrasound screening solely because someone takes semaglutide has uncertain value and is not a universal requirement.

Severe gastroparesis

Current labeling states that Wegovy is not recommended in severe gastroparesis.

Pregnancy

For weight and cardiovascular-risk indications, semaglutide is stopped when pregnancy is recognized, and FDA labeling recommends stopping at least 2 months before a planned pregnancy because of the long washout. MASH labeling uses a more individualized benefit-risk framing, so pregnancy guidance depends on the indication.

Surgery and anesthesia

Rare pulmonary aspiration events have occurred around general anesthesia and deep sedation, related to delayed gastric emptying. There is no single universal "stop X days before surgery" rule; management depends on current clinical guidance, the procedure, symptoms, aspiration risk and the anesthesia plan.

Hypoglycemia with other glucose-lowering drugs

Semaglutide stimulates insulin in a glucose-dependent way. Hypoglycemia risk matters much more when it is combined with insulin or sulfonylureas than when it is used without them.

Side effects

Most common

Gastrointestinal effects dominate: nausea, vomiting, diarrhea, constipation, abdominal discomfort and dyspepsia, especially around dose escalation.

Dysesthesia

Dysesthesia is altered or unpleasant skin sensation, including skin sensitivity, hyperesthesia, paresthesia, burning sensation, skin pain and allodynia. Current FDA labeling reports about 22% at 7.2 mg, 6% at 2.4 mg and 0.3% on placebo. FDA states that incidence increased with dose and circulating semaglutide concentration. Some affected patients needed dose reduction, temporary interruption or discontinuation, and some had recurrence after re-escalation. This is a confirmed dose-related safety signal.

Gallbladder disease

A labeled risk. Weight reduction itself contributes to gallstone formation, but gallbladder events were also more frequent with semaglutide in clinical trials.

Pancreatitis

Acute pancreatitis has been observed with GLP-1 receptor agonists, including semaglutide. This is an established warning; semaglutide does not commonly cause pancreatitis.

Kidney injury

Semaglutide has proven kidney-outcome benefit in appropriately selected patients with type 2 diabetes and CKD. At the same time, severe GI fluid losses can cause dehydration and acute kidney injury. Both can be true.

Diabetic retinopathy

A diabetic-retinopathy complication signal exists, especially in patients with pre-existing retinopathy and rapid glucose improvement. This does not prove direct retinal toxicity.

Heart rate

Wegovy labeling includes heart-rate increase as a warning. This is an established pharmacodynamic effect; it does not mean semaglutide inevitably causes arrhythmia.

Suicidal ideation

Older obesity-drug labeling carried warnings about suicidal ideation and behavior. In January 2026 FDA announced that its comprehensive review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of that warning from affected obesity labels. Suicidal ideation is not an established semaglutide-specific adverse effect.

Hair loss

Hair loss appears in current Wegovy adverse-reaction data. This does not prove semaglutide directly damages follicles; possible contributors include rapid weight loss, reduced calorie intake, low protein intake, nutritional changes and metabolic stress.

"Ozempic face"

This is a popular-media term, not a recognized semaglutide disease. Facial-volume loss can follow substantial weight reduction from many causes.

Compatibility

Combination logic

• Semaglutide + tirzepatide: tirzepatide already activates GLP-1R and GIPR, so adding semaglutide adds more GLP-1R agonism. Substantial receptor redundancy; no validated combined protocol.
• Semaglutide + retatrutide: retatrutide already agonizes GLP-1R, GIPR and GCGR. High receptor redundancy; no established combination regimen.
• Semaglutide + cagrilintide: cagrilintide acts mainly through amylin-related pathways, and controlled combination research exists as CagriSema. That does not validate arbitrary separate-vial community ratios or same-syringe mixtures.
• Compounded semaglutide + B12 / B6 / carnitine / NAD+: these combinations appear in compounding practice. They are common compounded combinations; combination superiority is not established.

Same-syringe compatibility

Clinical coadministration or mechanistic complementarity does not establish chemical compatibility, pH compatibility, physical stability, potency retention or same-syringe safety with other drugs or peptides. Evidence for the exact formulation is required.

Storage

Storage and the 28-day rule

There is no universal rule that all reconstituted semaglutide lasts 28 days refrigerated. Approved commercial products have formulation-specific storage data. A different compounded or lyophilized preparation needs its own formulation-specific stability evidence.

Research vials are not Wegovy or Ozempic

Approved injectable semaglutide products are manufactured as controlled finished formulations. A third-party lyophilized vial labeled "semaglutide" does not inherit the approved product's formulation, manufacturing controls, validated concentration, stability data, sterility assurance or clinical-trial evidence.

Regulatory and compounding status

FDA approval

Semaglutide is FDA approved as Wegovy injection, Wegovy tablets, Ozempic injection, Ozempic tablets and Rybelsus, each for specific indications. Wegovy HD (7.2 mg) was approved on March 19, 2026.

Compounded semaglutide

FDA continues to warn about unapproved compounded GLP-1 products and states that compounded products should not be represented as the same as FDA-approved drugs.

503B update: on April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List after concluding that it had not identified a clinical need for outsourcing facilities to compound these drugs from bulk drug substances. This is a proposed action. It does not make every individualized compounded semaglutide prescription unlawful.

Adverse-event reports: as of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide. These are meaningful pharmacovigilance data, but they do not prove that compounded semaglutide caused every reported event, and spontaneous reporting can be incomplete or affected by other clinical factors.

Semaglutide sodium and acetate

Semaglutide sodium and semaglutide acetate are not automatically interchangeable with the semaglutide base used in approved products, a distinction FDA has raised in compounding guidance. A COA showing high purity does not establish correct API identity or equivalence to the approved formulation: purity and molecular identity are separate questions.

Sources

1. U.S. Food and Drug Administration. FDA approves higher-dose semaglutide (Wegovy HD 7.2 mg), March 19, 2026. fda.gov press announcement
2. U.S. Food and Drug Administration. Wegovy (semaglutide) injection: current prescribing information, 2026. accessdata.fda.gov label 215256s029
3. U.S. Food and Drug Administration. Wegovy HD 7.2 mg: prescribing information, 2026. accessdata.fda.gov label 218316s007
4. U.S. Food and Drug Administration. Ozempic (semaglutide) tablets: current prescribing information, 2026. accessdata.fda.gov label 213051s030
5. Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PubMed 40961952
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
7. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
8. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
9. Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PubMed 38785209
10. Mademlis C, et al. Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health? Expert Rev Clin Pharmacol. 2025;18(10):1-5. PubMed 41070406
11. U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications, 2026. fda.gov drug safety communication
12. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded semaglutide. fda.gov compounding alert
13. U.S. Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss (compounded semaglutide adverse-event reports). fda.gov postmarket safety information
14. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B Bulks List, April 30, 2026. fda.gov press announcement
15. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. fda.gov drug alerts and statements